The Efficacy of Meloxicam as an Adjunct Therapy in the Treatment of Neonatal Calf Diarrhea Complex

Authors

  • C. G. Todd Department of Population Medicine, Unversity of Guelph, Guelph, Ontario, Canada
  • D. R. McKnight Kemptville College, University of Guelph, Kemptville, Ontario, Canada
  • S. T. Millman Department of Population Medicine, Unversity of Guelph, Guelph, Ontario, Canada
  • T. F. Duffield Department of Population Medicine, Unversity of Guelph, Guelph, Ontario, Canada
  • K. E. Leslie Department of Population Medicine, Unversity of Guelph, Guelph, Ontario, Canada

DOI:

https://doi.org/10.21423/aabppro20064741

Keywords:

calf diarrhea, Meloxicam therapy, oral electrolyte, antibiotic therapy

Abstract

Neonatal calf diarrhea complex has a significant impact on the dairy industry. The National Animal Health Monitoring System reports that diarrhea accounts for greater than 60% of pre-weaned calf deaths. A recent field study in Europe has identified beneficial effects of Meloxicam therapy in calves with diarrhea. This controlled trial examined the efficacy of Meloxicam administration in combination with oral electrolyte and antibiotic therapy for the treatment of calf diarrhea. Compared to control animals, the Meloxicam-treated calves experienced significant improvements in clinical parameters, such as hydration status, fecal consistency, rectal temperature and signs of visceral pain. Overall, calfrecovery from the episode of diarrhea was improved for calves receiving Meloxicam therapy, compared to placebo-treated calves. The objective of the current study was to examine the effects of Meloxicam administration on calf health, behavior and performance in calves with neonatal calf diarrhea complex in Ontario.

Cover image of the 39th Conference Proceedings: Three calves lying down in a pasture next to a white fence. Behind them, a rainbow spans over the distant hills. Yellow background.

Downloads

Published

2006-09-21

Issue

2006

Section

Research Summaries 2